A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors ; volume:16 ; number:1 ; day:7 ; month:7 ; year:2016 ; pages:1-10 ; date:12.2016
BMC cancer ; 16, Heft 1 (7.7.2016), 1-10, 12.2016
- Creator
-
Haense, N.
- Contributor
-
Atmaca, A.
Pauligk, C.
Steinmetz, K.
Marmé, Frederik
Haag, G. M.
Rieger, M.
Ottmann, O. G.
Ruf, P.
Lindhofer, H.
Al-Batran, S.-E
SpringerLink (Online service)
- DOI
-
10.1186/s12885-016-2449-0
- URN
-
urn:nbn:de:1111-2016071010591
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Haense, N.
- Atmaca, A.
- Pauligk, C.
- Steinmetz, K.
- Marmé, Frederik
- Haag, G. M.
- Rieger, M.
- Ottmann, O. G.
- Ruf, P.
- Lindhofer, H.
- Al-Batran, S.-E
- SpringerLink (Online service)
Other Objects (12)
Predictive factors in HER2-positive early breast cancer : endogenous HER2-specific immune response as an early predictive marker for pathologic complete response and disease-free survival
Untersuchungen zur prognostischen Bedeutung und biologischen Funktion von NK-Zell-Rezeptor-Liganden im Serum und Tumorgewebe von Patientinnen mit zervikalen intraepithelialen Neoplasien (CIN I-III) und Zervixkarzinom
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine
Purified anti-CD3 × anti-HER2 bispecific antibody potentiates cytokine-induced killer cells of poor spontaneous cytotoxicity against breast cancer cells
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Olaparib: Präzisionsmedizin beim Pankreas- und Prostatakarzinom : PARP-Inhibition in der onkologischen Praxis
Anti-CD3 monoclonal antibody as a possible therapeutic alternative in HAM/TSP
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
Anti-CD3 antibody treatment reduces scar formation in a rat model of myocardial infarction
Inhibition of T cell-mediated inflammation in uveitis by a novel anti-CD3 antibody
Predictive factors in HER2-positive early breast cancer : endogenous HER2-specific immune response as an early predictive marker for pathologic complete response and disease-free survival
Untersuchungen zur prognostischen Bedeutung und biologischen Funktion von NK-Zell-Rezeptor-Liganden im Serum und Tumorgewebe von Patientinnen mit zervikalen intraepithelialen Neoplasien (CIN I-III) und Zervixkarzinom
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine
Purified anti-CD3 × anti-HER2 bispecific antibody potentiates cytokine-induced killer cells of poor spontaneous cytotoxicity against breast cancer cells
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Olaparib: Präzisionsmedizin beim Pankreas- und Prostatakarzinom : PARP-Inhibition in der onkologischen Praxis
Anti-CD3 monoclonal antibody as a possible therapeutic alternative in HAM/TSP
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
Anti-CD3 antibody treatment reduces scar formation in a rat model of myocardial infarction
Inhibition of T cell-mediated inflammation in uveitis by a novel anti-CD3 antibody
Predictive factors in HER2-positive early breast cancer : endogenous HER2-specific immune response as an early predictive marker for pathologic complete response and disease-free survival
Untersuchungen zur prognostischen Bedeutung und biologischen Funktion von NK-Zell-Rezeptor-Liganden im Serum und Tumorgewebe von Patientinnen mit zervikalen intraepithelialen Neoplasien (CIN I-III) und Zervixkarzinom
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine
Purified anti-CD3 × anti-HER2 bispecific antibody potentiates cytokine-induced killer cells of poor spontaneous cytotoxicity against breast cancer cells
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Olaparib: Präzisionsmedizin beim Pankreas- und Prostatakarzinom : PARP-Inhibition in der onkologischen Praxis
Anti-CD3 monoclonal antibody as a possible therapeutic alternative in HAM/TSP
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
Anti-CD3 antibody treatment reduces scar formation in a rat model of myocardial infarction